Journal of the American Academy of DermatologyFeb 18, 2026

How GLP-1 Receptor Agonists Work and Their Possible Effects on Skin Health

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Feb 19, 2026

Abstract

The review highlights the significant weight loss benefits and multiple organ effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs).

GLP-1RAs originally developed for glycemic control also show effects on weight loss and metabolic health.
These agents influence multiple organ systems and have a broad cellular distribution.
GLP-1-based therapies are associated with immunomodulatory effects, reducing inflammation and promoting healing.
Evidence suggests potential benefits of GLP-1-based agents in dermatological conditions, including psoriasis and hidradenitis suppurativa.
Further research is needed to understand the specific mechanisms in skin biology and enhance their use in dermatology.

Simplified

The prevalence of obesity and type 2 diabetes mellitus (T2DM) continues to rise in the United States (U.S.) and worldwide, contributing to substantial morbidity and mortality through metabolic dysfunction and systemic inflammation. Glucagon-like peptide-1(GLP-1)-based therapies, originally developed for glycemic control, have since demonstrated significant weight loss benefits and multiple effects across multiple organ systems. This review provides an overview of the historical development and mechanistic underpinnings of GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, with emphasis on their broad cellular distribution and physiologic actions. Beyond their well-established roles in glucose regulation and β-cell function, GLP-1-based agents exert immunomodulatory effects, attenuating pro-inflammatory cytokine signaling while promoting anti-inflammatory pathways. Emerging evidence may support their relevance in dermatology, including improvement in psoriasis and hidradenitis suppurativa (HS), enhanced wound healing, and modulation of nociceptive signaling. These findings underscore the expanding therapeutic scope of GLP-1-based agents, suggesting potential utility in both systemic metabolic disease and dermatologic conditions. Continued investigation is warranted to clarify receptor-specific mechanisms in skin biology and to optimize integration of these therapies into dermatologic practice.

Full Text

Full text is available at the source.

View Full Text ↗

How GLP-1 Receptor Agonists Work and Their Possible Effects on Skin Health

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief